Regensburg 2025 – scientific programme

Parts | Days | Selection | Search | Updates | Downloads | Help

KFM: Fachverband Kristalline Festkörper und deren Mikrostruktur

KFM 14: Poster

KFM 14.2: Poster

Wednesday, March 19, 2025, 17:00–18:30, P1

Assessment of new cocrystals of amphotericin B and miltefosine (leishmanicidal pharmaceuticals) via powder X-ray diffraction analysis. — •Memoona Bibi, muhammad Iqbal Choudhary, and Sammer Yousuf — H.E.J. Research Institute of Chemistry, ICCBS, University of Karachi, Pakistan.

Cocrystals and other cutting-edge technologies offer substantial opportunities for patents that present multiple strategies for managing the life cycle of existing and novel drugs. The creation of cocrystals by employing suitable coformers represents a valuable approach toward stability, enhancement, and bio availability of pharmaceutical medications. The focal point of current study was co-crystallization of well-known commercially available anti-leishmanial drugs i.e. Amphotericin B and Miltefosine. Multiple cocrystals of amphotericin B and miltefosine were successfully synthesized. To prepare the co-crystals neat grinding method via mixer mill was applied. The characterization was conducted through powder X-ray diffraction revealing unique crystallinity and significant variation in 2θ values of cocrystals. DSC/TGA, UV, FTIR and melting point were also proceeded for further evaluation. The solubility studies of amphotericin B at pH 6.8, 7.4 and in distilled H2O in comparison with their co-crystals revealed promising results. Invitro testing of all co-crystals against L. major, L. donovani, and L. tropica demonstrated potent anti-leishmanial activity in comparison with reference standard drugs i.e. amphotericin B and miltefosine. However, cytotoxicity results revealed none of them exhibited cytotoxic effect against MTT (3T3) cell line.

Keywords: Amphotericin B; Miltefosine; Co-crystals; Leishmaniasis; Cytotoxicity